PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer by Cox, Orla T. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative
breast cancer
Author(s) Cox, Orla T.; Edmunds, Shelley J.; Simon-Keller, Katja; Li, Bo; Moran,
Bruce; Buckley, Niamh E.; Bustamante- Garrido, Milán F.; Healy,
Nollaig; O'Flanagan, Ciara H.; Gallagher, William M.; Kennedy,
Richard D.; Bernards, René; Caldas, Carlos; Chin, Suet-Feung; Marx,
Alexander; O'Connor, Rosemary
Publication date 2019-03-18
Original citation Cox, O. T., Edmunds, S. J., Simon-Keller, K., Li, B.,  Moran, B.,
Buckley, N. E., Bustamante-Garrido, M., Healy, N., O'Flanagan, C. H.,
Gallagher, W. M., Kennedy, R. D., Bernards, R., Caldas, C., Chin, S.-F.,
Marx, A. and O'Connor, R. (2019) ‘PDLIM2 is a marker of adhesion and
β-catenin activity in triple-negative breast cancer', Cancer Research,
79(10), pp. 2619-2633. doi: 10.1158/0008-5472.CAN-18-2787





Access to the full text of the published version may require a
subscription.
Rights © 2019, American Association for Cancer Research. All rights
reserved.
Embargo information Access to this article is restricted until 12 months after publication by
request of the publisher.































, Ciara H. O’Flanagan
1
, William M. 
Gallagher
3
















Cell Biology Laboratory, School of Biochemistry and Cell Biology, University College 
Cork, Cork, Ireland, 
2
Institute of Pathology, University Medical Centre Mannheim, 
Heidelberg University, Germany, 
3
School of Biomolecular & Biomedical Science, Conway 
Institute, University College Dublin, Dublin, Ireland, 
4
School of Pharmacy, Queens 
University Belfast, Belfast, Northern Ireland, 
5
Centre for Cancer Research and Cell Biology, 
Queens University Belfast, Northern Ireland, 
6
Division of Molecular Carcinogenesis and 
Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The 
Netherlands, 
7
Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, 
Cambridge, UK. 
 
Running Title: PDLIM2 enhances-catenin activity in TNBC 
Keywords: PDLIM2, adhesion, growth factor signaling, beta-catenin, TNBC biomarker. 
Abbreviations: TNBC; triple-negative breast cancer 
 
*Corresponding author: Rosemary O’Connor, Cell Biology Laboratory, School of 
Biochemistry and Cell Biology, University College Cork, Ireland. Phone: +353 21 490 1312. 
Email: r.oconnor@ucc.ie 
 
This study was supported by the Irish Cancer Society Collaborative Cancer Research Centre 
BREAST-PREDICT CCRC13GAL, Science Foundation Ireland Principal Investigator 
awards 11/PI/11139 and 16IA4505, a European Union FP7 Marie Curie Industry-Academia 
Partnerships and Pathways (IAPP) Programme 251480 BiomarkerIGF, and RATHER 
(Rational Therapy for Breast Cancer), a Collaborative Project funded under the European 
Union 7th Framework Programme (grant agreement no. 258967). 
 
Conflict of interest statement: The authors declare no potential conflicts of interest. 
Abstract: 225 words, Main text:  approx. 4852 words 
Number of Figures: 7 
Number of Supplementary Figures: 6,  
Tables: 2,  
Graphical Abstract: 1 
Number of References: 47  
 2 
Abstract: 
The PDLIM2 protein regulates stability of transcription factors including NF-κB and STATs 
in epithelial and hemopoietic cells. PDLIM2 is strongly expressed in certain cancer cell lines 
that exhibit an Epithelial-to-Mesenchymal phenotype, and its suppression is sufficient to 
reverse this phenotype. PDLIM2 supports the epithelial polarity of non-transformed breast 
cells, suggesting distinct roles in tumor suppression and oncogenesis. To better understand its 
overall function, we investigated PDLIM2 expression and activity in breast cancer. PDLIM2 
protein was present in 60% of tumors diagnosed as triple-negative breast cancer (TNBC), and 
only 20% of other breast cancer subtypes. High PDLIM2 expression in TNBC was positively 
correlated with adhesion signaling and β-catenin activity. Interestingly, PDLIM2 was 
restricted to the cytoplasm/membrane of TNBC cells and excluded from the nucleus. In 
breast cell lines, PDLIM2 retention in the cytoplasm was controlled by cell adhesion, and 
translocation to the nucleus was stimulated by IGF-1 or TGFβ. Cytoplasmic PDLIM2 was 
associated with active β-catenin and ectopic expression of PDLIM2 was sufficient to increase  
β-catenin levels and its transcriptional activity in reporter assays. Suppression of PDLIM2 
inhibited tumor growth in vivo, whereas over-expression of PDLIM2 disrupted growth in 3D 
cultures. These results suggest that PDLIM2 may serve as a predictive biomarker for a large 
subset of TNBC whose phenotype depends on adhesion-regulated β-catenin activity and 
which may be amenable to therapies that target these pathways.  
 
Statement of Significance: This study shows that PDLIM2 expression defines a subset of 










), and amplification of human epidermal growth factor receptor 2 (HER2
-
), and constitute 
15-20% of all breast cancers. TNBC displays considerable genetic heterogeneity, a high risk 
for distant metastasis, is refractory to many therapies, and often has a poor prognosis [1-5]. 
Although many studies have helped define subtypes within TNBC, the underlying drivers of 
this cancer are still unclear, and there is an urgent need for better biomarkers and therapeutic 
targets [5-7]. 
Growth factor and adhesion signaling have been strongly implicated in TNBC [8-11]. 
Our studies on Insulin-like Growth Factor-1 (IGF-1) signaling in cancer led us to identify the 
PDLIM2 (Mystique) protein [12], as a feedback regulator of IGF-1 and adhesion signaling 
[12-14]. PDLIM2 is a member of the PDZ-LIM domain family encoded by a locus on 
chromosome 8p21 [12, 15, 16], a region that is associated with metastasis and often disrupted 
in cancer [17]. Located at the cytoskeleton and nucleus of epithelial cells and hemopoietic 
cells, PDLIM2 regulates the stability and activity of important transcription factors including 
STATs, NF-κB and IRFs [12, 18-21]. PDLIM2 can suppress cellular transformation [12, 13, 
16], and it may be repressed by methylation in breast cell lines [22, 23]. PDLIM2 inactivation 
has also been reported in classical Hodgkin and anaplastic large cell lymphoma [24]. On the 
other hand, PDLIM2 is robustly expressed in breast and prostate cancer cells that exhibit a 
migratory phenotype [13, 16], and sustains a transcription programme for Epithelial to 
Mesenchymal Transition (EMT) [21]. In line with this, PDLIM2 expression has been linked 
to highly aggressive ovarian cancer [25], lymph node metastasis in low-grade breast cancers 
[26] and was identified as a moderate dependency gene in basal breast cancers [27]. It has 
also been linked to the growth of Neurofibromatosis 2 (NF2)-associated menginioma and 
schwannoma [28].  
In the non-tumorigenic MCF10A breast epithelial cell line, PDLIM2 is required for 
maintaining cell polarization and 3D acinar formation [14], and PDLIM2 expression 
increases upon retinoic-acid induced differentiation of breast cancer cells [23]. However, 
although PDLIM2 expression has been linked with tumor suppression and with sustaining a 
migratory phenotype, it is still unclear what it contributes to the progression or phenotype of 
any subgroup of breast cancer. Here, we investigated this by assessing PDLIM2 expression in 
different cohorts of breast tumors and manipulating its expression in cell lines.  We found 
that PDLIM2 is expressed in a subset of triple-negative breast cancers (TNBCs; 50-60%), and 
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in approximately 20% of other breast cancer subtypes. In triple-negative tumors and cell 
lines, cytoplasmic PDLIM2 promotes the accumulation of active β-catenin. Our study 
suggests that PDLIM2 mediates adhesion and growth factor signals derived from the tumor 
microenvironment to enhance β-catenin activation in a large proportion of TNBCs.  
 
Materials and Methods 
 
Cell Culture and Assays 
Cell lines were purchased from ATCC, except CAL-51 (DSMZ) and authentication 
established by PCR-single-locus-technology (Eurofins Medigenomix, Forensik GmbH, 
Ebersberg, Germany), up to November 2018. MDA-MB-231-LUC2 cells were purchased for 
in vivo experiments (Caliper Life Sciences). All cells were tested monthly for mycoplasma by 
specific DNA staining and maintained as previously described [14, 29, 30], up to 6-8 weeks 
for use in experiments. Further details can be found in supplementary methods: Tables 1, 3. 
For serum starvation and growth factor stimulation, cells were incubated in serum-
free medium for 4hr prior to stimulation, or not, with 10ng/ml TGF-β1 or IGF-1. For non-
adherent conditions, cells were trypsinized, centrifuged and washed prior to re-suspension in 
complete medium into 50ml tubes. Cells were incubated for 4 hours at 37
o
C, with gentle 
rotation. Alternatively, cells were seeded on petri dishes coated with 100µl/cm
2 
of Polyhema 
(6mg/ml) (Sigma, Dublin, Ireland).  
For wound healing assays, confluent monolayer cultures were wounded by scoring 
with a sterile pipette tip, and imaged at 0hr and 24hr post-wounding. Wound widths were 
measured as described in Supplementary Methods. 
Colony formation was measured by assessing plating efficiency. MDA-MB-231-
LUC2 cells were seeded at 5 x 10
2
 cells/well in 6 well plates, (minimum triplicates per 
clone). After 9-10 days, cells were stained with 0.01% crystal violet and colonies of more 
than 50 cells were counted.  
For 3D on Top assays, cells were cultured on matrigel with matrigel-supplemented 
medium, as described by Kenny et al [31] and monitored over 4 days. Entire 3D cultures 
were extracted for western blot analysis of protein expression as described [31].  
In vivo bioluminescence imaging of tumor spread 
Two separate clones of MDA-MB-231-LUC2 cells stably expressing shRNA scramble 
control or shRNA targeting PDLIM2 (1 ×10
6
 cells), were injected into the tail vein of 4-5 
 5 
week old female HsdOla:MF1-Foxn1
nu
 mice (Harlan, UK; n = 6-7 per group, randomized; 3 
separate cohorts). The Bioluminescent signal (luminescence counts) per animal per cell clone 
and images were collected after 45-49 days by using the IVIS
®
 Spectrum in vivo imaging 
system (PerkinElmer, Dublin, Ireland). These experiments were performed under licence to 
R. O’Connor from the Irish Department of Health and protocol approval by University 
College Cork Animal Experimentation Ethics Committee (#2012/008). Further details are in 
supplementary Methods.   
 
Cell lysates, Subcellular fractionations, Western blotting and Densitometry  
Total cell protein was extracted using RIPA buffer and subcellular fractionations were 
performed as described previously [20, 32]. Western blot analyses were performed using the 
Odyssey Image scanner system and protein expression levels were normalized to protein 
loading control by densitometry using Licor Image Studio software as previously described 
[14, 20, 21, 32].  
 
Breast Cancer tissue sample collections and Immunohistochemistry 
All tissues were stained using a PDLIM2 mouse monoclonal antibody (Abcam). Details of 
immunohistochemistry (IHC) staining procedures used for each sample collection are 
described in supplementary methods.  
Northern Ireland Biobank (NIB) cohort: Breast Cancer Tissue Microarrays were generated 
from Formalin-fixed paraffin-embedded primary tumor blocks as previously described [33]. 
Each tumor was represented by three independent cores. Breast Cancer subtypes were 
determined from biomarker expression, and classified according to St Gallen International 
Expert Consensus [34] as: Luminal A (ER and/or PR positive, HER2 negative); Luminal B 
(ER and/or PR positive and HER2 negative (HER2-) or HER2 overexpressed/amplified 
(HER2+)); HER2 enriched (non-luminal, ER and PR negative and HER2 
overexpressed/amplified); Basal-like/Triple negative (ER, PR and HER2 negative).  
RATHER TNBC cohorts: Slides from the Netherlands Cancer Institute (NKI) and 
Cambridge University (CAM) contained tissue cores from individual patients within the 
cohorts [35], and we analyzed IHC staining of tumor samples from 128 TNBC patients. 
Further details on RATHER cohorts analyses are in supplementary Methods. 
Heidelberg samples: Breast Cancer Tissue sections were prepared from TNBC 
biopsies at the University Medical Centre Mannheim as described previously [36].  
Further details are in supplemental methods. Written informed consent and ethical approval 
was obtained at each Institution [33, 35, 36]. 
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RNA extraction, quantitative PCR, DNA, shRNA and siRNA Transfections 
RNA extraction, cDNA synthesis and quantitative PCRs were performed as previously 
described [21], with details and primer sequences in supplementary methods/ Table 2.  
MDA-MB-231-LUC2 cells were transfected with pSUPER vectors encoding shRNAs 
targeting PDLIM2 (shPDLIM2) or control shRNA (shScramble), and BT549 cells with 
pcDNA3-HA-Empty Vector (EV) or HA-PDLIM2 using Lipofectamine 2000. Stable clones 
were generated by selection in G418 [12, 21]. HEK293T cells were transiently transfected 
with HA-EV or HA-PDLIM2 using Calcium Phosphate protocol [32]. HCC1806 were 
transiently transfected with siRNA negative control and 2 different siRNAs targeting 
PDLIM2 using oligofectamine [12]. Further details are in supplementary Methods. 
 
β-catenin/Tcf transcriptional reporter activity  
HEK293T cells grown on 96-well OptiPlate microplates (PerkinElmer) were transfected with 
the TOPflash plasmid, which contains three copies of the Tcf/Lef sites upstream of a 
thymidine kinase (TK) promoter and the firefly luciferase gene, and the FOPflash, which 
contains mutated copies of Tcf/Lef sites using Lipofectamine 2000. Cells were co-transfected 
with 0.2 µg of internal control reporter Renilla reniformis luciferase construct (pRL-TK; 
Promega) to normalize transfection efficiency, and luciferase activity was measured using a 
dual luciferase Assay System kit (Promega). 
Immunofluorescence staining 
Cells were fixed with 4% paraformaldehyde, probed with primary antibodies followed by 
Alexa 488- or Cy3-conjugated secondary antibodies and/or TRITC-phalloidin. Nuclei were 
visualized with Hoechst dye and imaged as described previously [12, 14], and in 
supplementary methods.   
 
RATHER cohorts RPPA, gene expression and subtype survival analysis 
RNA was purified, amplified, labeled and hybridized to the Agendia custom-designed whole 
genome microarrays (Agilent Technologies) and raw fluorescence intensities quantified, as 
previously described [35]. GEO accessions are GSE66647 (RPPA) and GSE68057 (RNA 
microarray expression). Further details of analyses of the RATHER cohorts are in 
Supplementary Methods.  
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Kaplan-Meier survival analysis was performed using the SPSS statistics software (IBM). 
Univariate analysis was performed using the Cox regression model to illustrate the 
relationship between PDLIM2 protein expression and breast cancer-specific survival (BCSS), 
recurrence-free survival (RFS) and distant recurrence-free survival (DRFS), respectively. 
Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were evaluated for each 
survival outcome using the Cox regression model.  
 
Statistical Analysis: 
Graphs were prepared using GraphPad Prism. Data were analyzed for statistical significance 
using Fisher’s exact test, one way ANOVA or Student’s t-test as indicated in legends. A p-
value of <0.05 was deemed significant and graded p-values are denoted as follows: *p≤0.05; 
**p≤0.005; ***p≤0.0005, unless otherwise noted.  
 
Results 
PDLIM2 expression is enriched in Triple Negative Breast Cancer  
To gain insight into how PDLIM2 contributes to human breast cancer, we first assessed its 
expression in tissue microarrays (TMAs) using IHC scored as negative (0), low (1), moderate 
(2) or high (3).  Images representing the relative intensities of these IHC staining scores are 
shown in Suppl. Fig. 1A. In a TMA representing 248 breast tumors (Northern Ireland 
Biobank; NIB), PDLIM2 was expressed in 25.8% of all tumors (Fig. 1A). By separating these 
tumors using the Gallen scores of tumor classification [34], it was clear that the majority of 
Luminal A (HER2-negative), Luminal B-HER2-negative or -positive and HER2-enriched 
tumors did not express PDLIM2 (Fig. 1B, C). However, within the basal/TNBC samples 
more than half (53%) of tumors expressed PDLIM2 (Fig. 1B, C). Interestingly, PDLIM2 
expression in tumor-associated stroma or tumor-infiltrating leukocytes was evident in 30-
40% of all non-TNBC types in the TMA, and again, expression was proportionately higher in 
TNBC (61.8%; Fig. 1D, E, Suppl. Fig. 1B,C). Overall, 70% of PDLIM2-positive tumors (all 
subtypes) had PDLIM2-positive stroma, while within PDLIM2-negative tumors, 50% of 
TNBC and 30% of non-TNBC had PDLIM2-positive stroma (Suppl. Fig. 1C). PDLIM2 
staining in TNBC and non-TNBC TMAs are shown in Fig. 1F and Suppl. Fig. 1D 
respectively.  
In summary, PDLIM2 is expressed in more than 50% of TNBC tumor cells and 60% 
have PDLIM2-positive stroma, while in other breast cancer subtypes, it is expressed in 
approximately 20% of tumors and 40% of stroma.  
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The PDLIM2 protein is widely expressed in TNBC 
PDLIM2 association with TNBC was further tested in additional TNBC cohorts. These were 
from the RATHER consortium (www.ratherproject.com), which includes cohorts from the 
Netherlands Cancer Institute, (NKI, n=71) and the University of Cambridge, UK (Cam; 
n=57). We also tested a smaller cohort (n=15) from Heidelberg University. As can be seen in 
Figure 2A, PDLIM2 was expressed in 53% of TNBC from the NIB cohort (data from Fig.1), 
72% of the NKI cohort, 47% of the CAM cohort and 70% of the Heidelberg cohort (Figs. 2A, 
B). The distribution of weighted IHC scores for PDLIM2 staining is shown in Suppl. Fig. 2A. 
Overall, PDLIM2 was expressed in 60% of TNBCs across the four cohorts (Fig.  2C), and 
was low or absent in neighboring normal tissue, as shown in Suppl. Figure 2B (Heidelberg 
cohort). Interestingly, PDLIM2 is present in immune cells (mostly lymphocytes) surrounding 
epithelial ducts in this normal tissue (Suppl. Fig. 2B). 
We next asked whether PDLIM2 expression could be correlated with survival and/or 
clinicopathological features. No significant correlation was found with PDLIM2 expression 
and overall survival in TNBC patients from the NIB cohorts, and in the RATHER cohorts, 
PDLIM2 was not significantly correlated with outcome (breast cancer specific-, recurrence 
free-, or distant recurrence-free survival; Suppl. Fig. 2C). Similar trends were observed when 
data were segregated into weighted scores, and there was no significant association with 
histological grade, number of positive lymph nodes, or tumor size (Suppl. Fig. 2C).  
To test whether PDLIM2 is associated with specific TNBC subtypes we applied the 
80 gene signature from Burstein et al., [6] to the RATHER cohorts (Fig. 2D). The majority of 
tumors were classified as mesenchymal (MES), but there was no significant correlation of 
PDLIM2 with any subtype (Fig. 2E; Suppl. Fig. 3A and B). However, trends indicated higher 
PDLIM2 expression in the Basal-like Immune Activated (BLIA) and Suppressed (BLIS) 
subtypes (the latter of which is associated with poorest outcomes [6]), compared with MES or 
Luminal Androgen Receptor (LAR) subtypes (Suppl. Fig. 3B, C). Interestingly, in these 
analyses, we noted that PDLIM2 mRNA levels were not strongly correlated with PDLIM2 
protein expression (Suppl. Fig. 3D).  
Taken together, the data demonstrate that PDLIM2 is expressed in approximately 
60% of tumor cells derived from four cohorts of TNBC, but is not definitively linked to 
TNBC subtypes or clinical outcomes. 
 
PDLIM2 is restricted to the cytoplasm in TNBC tumors.  
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Since PDLIM2 subcellular location has previously been associated with integrating adhesion 
signals with transcription factor stability/activity [12, 20, 21], we next analyzed its location in 
TNBC tissue.  It was clear that PDLIM2 is predominantly expressed at the 
cytoplasm/membrane and excluded from the nucleus in tumor cells (Fig. 3A). By quantifying 
PDLIM2 staining at the cytoplasm/membrane or also in the nucleus (nuclear-only expression 
was not observed in tumor cells), it was evident that PDLIM2 was restricted to 
cytoplasmic/membranous areas (Fig. 3B, C). This is in contrast to high levels of nuclear 
PDLIM2 in stromal cells (Fig. 1F insets, Suppl. Fig. 2B and 3E).  
 To determine functional significance for cytoplasmic PDLIM2 in TNBC, we used 
available reverse phase protein array (RPPA) and RNA profiling data for the RATHER 
cohorts, and asked whether PDLIM2 expression was associated with signaling pathways, or 
with transcription factor activity. Included in these analyses were 63 proteins and 139 genes 
with known or anticipated links to PDLIM2 function [12, 14, 18, 20, 21], (Suppl. Tables I 
and II). The Wilcoxon Rank Sum test was used to determine significance. RPPA data showed 
that high levels of phospho-β-catenin (serine 675; active) were significantly correlated with 
PDLIM2-positive tumors (Fig. 3D, Suppl. Table I). Phospho-MET (Tyrosine 1349) and the 
adhesion-associated proteins fibronectin and FAK, were also high in PDLIM2-positive 
tumors. In contrast, mTOR and Ki67 were low in PDLIM2-positive tumors (Fig. 3D). 
Interestingly, although the expression levels of several genes previously shown to be 
regulated by PDLIM2 [21], were significantly different in PDLIM2- negative and -positive 
tumors, mRNA levels corresponding to the differentially expressed proteins within the RPPA 
data were not significantly different (Suppl. Table II and IIb).  
 Overall, these data demonstrate that PDLIM2 expression in TNBC is restricted to the 
cytoplasm and this positively correlates with β-catenin activity and adhesion signaling.  
 
PDLIM2 protein expression in TNBC cell lines is associated with adhesion and β-
catenin levels. 
To further test PDLIM2 association with specific signaling pathways in TNBC, we 
interrogated RNAseq and RPPA datasets available for approximately 80 breast cell lines [30]. 
PDLIM2 is not represented in the RPPA analysis but is present in the RNAseq data. Given 
the observed lack of correlation between PDLIM2 mRNA and protein expression in the 
tumor samples (Suppl. Fig. 3D), we first tested whether PDLIM2 mRNA could be correlated 
with protein expression in cell lines, using eight TNBC cell lines from the Marcotte study 
[30], and the triple-negative, non tumorigenic breast cell line, MCF10A, (classifications in 
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Suppl. Fig. 4A). In agreement with observations in tissues, we found that a subset of breast 
cell lines expressed high levels of PDLIM2 protein, whereas others did not (Fig. 4A and B).  
Analysis of the RNAseq dataset from the triple-negative (TN) cell lines [30] 
demonstrated that PDLIM2 RNA levels do not significantly correlate with protein expression 
(Suppl. Fig. 4B). The PDLIM2 gene encodes several RNA variants including PDLIM2 RNA 
variants 1, 2 and 3 (NM_198042, NM_021630, NM_176871; also referred to as Mystique 1, 
2, 3). We previously reported that PDLIM2 protein is encoded by PDLIM2 variant 2 [12, 16], 
and in the 9 TN cell lines, levels of PDLIM2 variant 2 mRNA correlated well with protein 
(Fig. 4 C), whereas variant 3 mRNA was generally inversely correlated with protein (Fig. 4 
D). PDLIM2 variant 1 was barely detectable. Thus, since RNAseq data may include all 
PDLIM2 RNA transcripts, it cannot be used to infer PDLIM2 protein expression. Moreover, 
since PDLIM2 mRNA levels did not correlate with differentially expressed proteins in the 
RATHER cohorts (Fig. 3, Suppl. Tables I and II, IIb), our analyses indicate that PDLIM2 
mRNA expression profiles in cancer cohorts do not reflect protein expression or function. 
This disparity may also explain why total PDLIM2 mRNA does not correlate strongly with 
clinical outcomes. 
 Using the nine TN breast cell lines, we next asked whether PDLIM2 protein correlates 
with adhesion signals and β-catenin, as was observed in the RPPA data (Fig. 3D). β1-integrin 
was tested as a marker of extracellular matrix (ECM) adhesion, and we previously reported 
that PDLIM2 is essential for feedback regulation of β1-integrin signals [14]. E-cadherin and 
β-catenin are markers of cell-cell adhesion. β1-integrin was observed to be generally higher 
in PDLIM2-positive than PDLIM2-negative breast cell lines (Fig. 4E, G, Suppl. Fig. 4C). 
Furthermore, E-cadherin and β-catenin were also expressed at higher levels in PDLIM2-
positive than PDLIM2-negative cells (Fig. 4E-G), with the exception of MDA-MB-231 cells 
where E-cadherin is suppressed by methylation [37].  In addition, β-catenin phosphorylated 
on Serine 675 was higher in PDLIM2-positive TN cells (Fig. 4E). Furthermore, levels of 
phospho-EGFR and phospho-IGF-1R were high in PDLIM2-positive TN cells (Suppl. Fig. 
4D, E), although there was no clear correlation between phospho-c-MET and PDLIM2 
expression (Suppl. Fig. 4F). 
Overall, we conclude that PDLIM2 expression is associated with high levels of cell 
adhesion markers, active growth factor receptors and β-catenin.  
 
PDLIM2 shuttling from cytoplasm to nucleus is stimulated by adhesion and growth 
factors.  
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Although PDLIM2 is restricted to the cytoplasm of TN tumors (Figs. 1-3), it could be 
observed in the cytoplasm and nucleus of cultured cell lines by both immunofluorescence and 
sub-cellular fractionation, (Fig. 5 A, B, Suppl. Fig. 5A, B). These observations suggest that 
cell adhesion and growth factors promote PDLIM2 shuttling between the cytoplasm and 
nucleus, so we tested this further. We found that under non-adherent culture conditions, 
PDLIM2 accumulates in the nucleus (Suppl. Fig. 5B, C). De-adhesion of MCF10A cells for 
24h was sufficient to reduce PDLIM2 in the cytoplasm and induce accumulation in the 
nucleus, even under serum-starved conditions (Fig. 5C, D, Suppl. Fig. 5B, C). Re-adhesion of 
cells for up to 24hr was sufficient to restore cytoplasmic PDLIM2 with a concomitant 
decrease in nuclear levels (Fig. 5C). Thus, cell adhesion is necessary and sufficient for 
nuclear exclusion of PDLIM2.  
Serum starvation caused markedly decreased nuclear and increased cytoplasmic 
PDLIM2 (Fig. 5 E-H, Suppl. Fig. 5C). Stimulation of MCF10A with either TGF beta (Fig. 5 
E, G, H) or IGF-1 (Fig. 5F, G) promoted translocation of PDLIM2 into the nucleus over time. 
Interestingly, the substantial retardation of cytoplasmic PDLIM2 protein mobility, which we 
previously confirmed as serine phosphorylation [20], was less evident in the nuclear fractions 
(arrows; Fig. 5E, F), indicating that PDLIM2 serine phosphorylation facilitates it cytoplasmic 
sequestration. Overall, these data show that adhesion and growth factor signaling in TN 
breast cells control PDLIM2 phosphorylation and sub-cellular localization.  
 
PDLIM2 expression is sufficient to activate β-catenin in TNBC 
Since PDLIM2 expression correlates with active β-catenin (Fig. 3D, Fig. 4E), we next asked 
whether PDLIM2 enhances β-catenin activity by using two approaches. First, we assessed 
active β-catenin in cell lines using an antibody that detects β-catenin only when it is not 
phosphorylated on serine 45 and therefore active [38]. This showed that PDLIM2-expressing 
cells generally express active β-catenin (Fig. 6 A). Exceptions were MDA-MB-231 cells, 
which express PDLIM2 in the presence of low β-catenin, and HS578T which do not express 
PDLIM2 but have high active β-catenin expression. Similar results were observed using the 
antibody that detects active β-catenin phosphorylated on serine 675 [38, 39] (Fig. 4E, Suppl 
Fig. 5D). Immunofluorescence staining illustrated that active β-catenin is present at the 
plasma membrane, throughout the cytoplasm and in the nucleus of PDLIM2-positive cells 
(Fig. 6B). Interestingly, in cells with low PDLIM2, active beta catenin is predominantly at the 
plasma membrane (Fig. 6B). 
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The second approach was to test the effects of ectopic HA-PDLIM2 expression on β-
catenin activity. In BT549 cells, HA-PDLIM2 was mostly evident in the cytoplasm and at the 
actin cytoskeleton (Suppl. Fig. 5E). Higher total and active β-catenin levels (Fig. 6C, Suppl. 
Fig. 6A) were observed in the cytoplasm and nucleus (Suppl. Fig. 6A, B), and the migratory 
potential was enhanced compared to controls (Suppl. Fig. 6C).  Furthermore, ectopic 
expression of PDLIM2 was sufficient to activate β-catenin in HEK293T cells in luciferase 
reporter assays (Fig. 6D, E).  PDLIM2 suppression had minor effects on the levels of β-
catenin and adhesion proteins, in HCC1806 cells and MDA-MB-231-LUC2 cells (Suppl. Fig. 
6E, F). 
Since active β-catenin is associated with PDLIM2 in TNBC tissues and cell lines (Fig. 
3, Fig. 6A, B), and PDLIM2 is restricted to the cytoplasm of TNBC tumor cells (Fig. 3), we 
next asked whether the sub-cellular localization of PDLIM2 is important for β-catenin 
expression and activation. To test this, we used cell detachment to induce nuclear 
accumulation of PDLIM2 and serum starvation to induce nuclear exclusion, and then 
measured β-catenin levels and phosphorylation (activity) status in PDLIM2-positive and -
negative cells. As expected, (Fig. 5, Suppl Fig. 5, [12, 20]), cells in suspension exhibited less 
cytoplasmic PDLIM2 than adherent cells, with a concomitant accumulation of nuclear 
PDLIM2 (Fig. 6F, Suppl. Fig. 6G, H). These cells showed a clear reduction in active β-
catenin levels in both the cytoplasm and nucleus that was not evident in PDLIM2-negative 
cells. Serum starvation had little effect on levels of active β-catenin, indicating that nuclear 
PDLIM2 is not directly involved in regulating β-catenin levels or activity (Suppl. Fig. 6H, I).  
We also confirmed that over-expressed HA-PDLIM2 accumulated more in the nucleus than 
in the cytoplasm in non-adherent BT549 cells, and this was accompanied by a marked 
reduction in active β-catenin, especially in the nucleus (Fig. 6G).  
Overall, we conclude that PDLIM2 accumulation in the cytoplasm (and out of the 
nucleus) enhances nuclear levels of active β-catenin. 
 
PDLIM2 suppression impairs TNBC tumor spread in vivo and alters spheroid growth.  
 In a previous study PDLIM2, suppression in DU145 prostate cells was shown to reverse the 
EMT phenotype characterized by re-expression of epithelial markers and loss of directional 
migration [21]. In that study we also showed MDA-MB-231-LUC2 cells with stably 
suppressed PDLIM2 exhibited enhanced proliferative rates and reduced growth in soft 
agarose compared to controls. As can be seen in Figures 7A and B, two clones of MDA-MB-
231-LUC2 cells stably expressing shRNA targeting PDLIM2 (shPDLIM2) exhibited greatly 
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reduced colony formation (plating efficiency) compared to controls (shScr).  To test the in 
vivo significance of PDLIM2 suppression in TNBC, we assessed in vivo tumour spread of 
these MDA-MB-231-LUC2 clones in nude mice.  Each of the shPDLIM2 clones exhibited 
little if any tumor burden after 45-49 days compared to controls, noting that control shScr 1 
cells exhibited better growth in vivo than shScr 2 (Fig. 7C). This result is consistent with 
reduced clonogenic growth and migratory potential previously observed with PDLIM2 
suppression [21], and suggests that high PDLIM2 may facilitate breast cancer progression. 
To further test PDLIM2 function, we assessed the effects of PDLIM2 overexpression 
on BT549 3D cell growth using 3D ‘on top’ cell culture assays [31]. In control BT549 
cultures, cells formed stellate 3D structures that have previously been associated with an 
invasive phenotype [31]. However, BT549 cells stably expressing HA-PDLIM2 with higher 
active β-catenin, initially formed more rounded, small clustered structures than controls at 
day 2, and failed to fully adopt the stellate morphology by day 4 (Fig. 7D, E). These results 
indicate that PDLIM2 regulates the pathway controlling the stellate phenotype and also 
indicates that β-catenin activity is regulated during this reversible process. 
 
Discussion: 
Although several studies have characterized distinct types of TNBC [1-3, 6, 7], there remains 
an urgent need for biomarkers with prognostic value or to predict TNBC subgroups that 
would be amenable to novel therapies. Here, we found that the PDLIM2 protein is enriched 
in triple-negative breast cancers (overall approximately 60%), while it is less frequently 
expressed in other breast cancers. Furthermore, the correlation of PDLIM2 expression with β-
catenin activity and adhesion signaling suggests it defines a large cohort of TNBC with 
similar features. A direct link between PDLIM2 expression in TNBC and clinicopathological 
parameters was not established. However, this may be due to TNBC heterogeneity and the 
fact that PDLIM2 mRNA profiles in available TNBC databases actually represent several 
PDLIM2 mRNA variants, while only one mRNA variant (2) encodes protein. Our conclusion 
that the PDLIM2 protein is a marker for a large subset of TNBC is further supported by 
published genomic studies, including a gene dependency screen, that identified PDLIM2 as a 
moderate dependency gene in basal TNBC and functionally linked this to cell adhesion [27]. 
Interestingly, this study also reported that basal TNBC is addicted to proteasomal activity, 
while genes encoding components of the proteasome and the COP9 signalosome (CSN) have 
been described as essential in TNBC basal A cell lines [30]. These observations are all 
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consistent with the reported actions of PDLIM2 in shuttling between the cytoskeleton and 
nucleus to regulate transcription factor stability [19, 21, 40], via association with the COP9 
signalosome [21].  
Suppression of PDLIM2 in MDA-MB-231 (and DU145) cells is sufficient to impair 
migratory potential and clonogenic growth [21], and as shown here, to impair in vivo spread 
of MDA-MB-231-LUC2 cells, while re-introduction of PDLIM2 into BT549 TNBC cells 
alters their invasive growth in 3D cultures and enhances directional migration. The exclusion 
of PDLIM2 from the nucleus of tumor cells, and the effects of adhesion and growth factors 
on promoting PDLIM2 translocation from the cytoplasm to nucleus in cell cultures, indicate 
that adhesion signaling promotes cytoplasmic retention of PDLIM2 in TNBC to regulate its 
function.  Moreover, TN cell lines expressing cytoplasmic PDLIM2 generally also expressed 
high levels of β1-integrin, E-cadherin, β-catenin, and phosphorylated IGF-1 or EGF 
Receptors. However, although PDLIM2 suppression enhanced expression of integrins and 
ECM proteins in a MCF10A 3D model [14], suppression of PDLIM2 in TNBC cell lines did 
not have a significant effect on the levels of β1-integrin, for example. This may be expected 
considering the high levels of adhesion proteins in PDLIM2-expressing TNBC cells, and that 
PDLIM2 is itself regulated by, and a component of adhesion signaling in these cells.  Overall, 
we propose that PDLIM2 functions to maintain a polarized phenotype associated with cell-
cell adhesion in normal epithelial cells, but in cancer cells, it is a component of adhesion 
signaling that promotes loss of cell polarization, tumour growth, and motility.  
Our findings indicate that β-catenin activity is a key output of cytoplasmic PDLIM2 
in TNBC. Levels of active β-catenin were significantly elevated in PDLIM2-positive tumors 
and ectopic expression of PDLIM2 was sufficient to induce β-catenin expression and activity 
in cell lines. This is consistent with suppression of PDLIM2 in EMT-like cells causing 
reduced β-catenin nuclear activity [21]. Several studies have linked canonical and atypical 
WNT/β-catenin signaling to breast cancer, although the role of β-catenin is complex [41-44]. 
Canonical WNT signaling in TNBC may promote stabilization of β-catenin in the cytoplasm 
and subsequent transcription of genes involved in EMT [44]. However, elevated β-catenin at 
the plasma membrane has been linked with a good prognosis in TNBC [42], while low β-
catenin at cell membranes in EGFR-positive TNBC has been associated with poor survival 
[45]. Low levels of E-cadherin at cell membranes may also correlate with elevated β-catenin 
activity and poor survival in TNBC [46].  
How PDLIM2 integrates adhesion and growth factor signaling to enhance β-catenin 
phosphorylation and activation is not fully established. It is likely that PDLIM2 mediates cell 
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adhesion-dependent phosphorylation and relocation of β-catenin to facilitate its subsequent 
nuclear activity. This is supported by our observations that cell de-adhesion reduces 
cytoplasmic PDLIM2 levels and phosphorylation/nuclear accumulation of active β-catenin, 
and that ectopic expression of PDLIM2 enhances β-catenin phosphorylation on serine 675 
and its nuclear accumulation. Importantly, we also observed that although active β-catenin is 
low in PDLIM2-negative cell lines, it was predominantly at the plasma membrane or cell-cell 
contacts, whereas, in PDLIM2-positive cells, it was localized in the cytoplasm and nucleus. 
This suggests that PDLIM2 is not implicated in basal β-catenin phosphorylation, but rather, it 
facilitates the release of β-catenin from the membrane, thereby enabling its stabilization, 
phosphorylation and subsequent activation. Interestingly, growth factor and adhesion signals 
have recently been reported to act through cellular kinases such as SRC and PAK to enhance 
β-catenin phosphorylation on serine 675, and its subsequent activation [39, 47].  
In summary, PDLIM2 is a marker for a large subgroup of TNBC that is driven by 
adhesion, growth factor signals and β-catenin activity. The identification of a potential new 
protein marker to classify functional subsets of TNBCs across previously defined subtypes is 
an important development. While PDLIM2 per se may not have a prognostic role, it could be 
a predictive biomarker to stratify TNBC for therapies that target the signaling pathways 
regulated by PDLIM2 or that directly target active β-catenin. 
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Figure 1:  
PDLIM2 expression is enriched in Triple Negative Breast Cancer 
A: A Breast Cancer TMA of 248 samples from the Northern Ireland Biobank (NIB) was 
stained for PDLIM2 expression by immunohistochemistry. PDLIM2 expression was scored 
as negative (0), low (1), moderate (2) or high (3). Percentages of total negative or positive 
samples from the entire cohort are shown. B, C: The TMA samples were classified according 
to Breast Cancer subtype and percentage of PDLIM2 negative versus positive (B) and 
PDLIM2 expression scores within each tumor type was assessed (C). Sample numbers for 
each Breast cancer subtype are shown in brackets in B. D, E: The percentage of samples with 
PDLIM2 negative and positive expression in Tumor stroma/infiltrating cells was assessed 
and quantified across the cohort (D) and within each Breast Cancer subtype (E). F: Panels i-
iv: Representative micrographs of PDLIM2 IHC staining in TNBCs showing tumor cell and 
stromal cell negative staining (i); Tumor positive/stroma negative (ii); Tumor negative/stroma 
positive (iii), and tumor positive/stroma positive (iv). Insets show higher magnification 
images demonstrating PDLIM2 staining in Tumor (T) or stroma (S) cells. ***P<0.0001, 
**P<0.005, *P<0.05, Fisher’s exact test comparing PDLIM2 positive and negative tumors in 
TNBC versus each non-TNBC subtype; ### P<0.0001 denotes TNBC versus all non-TNBC 
subtypes in B, C and E. In C, only IHC score 1 tumors were statistically significant. 
 
Figure 2:  
PDLIM2 is expressed in a subset of TNBCs 
A. PDLIM2 expression was examined and quantified in three cohorts of TNBC samples; 
RATHER Netherlands Cancer Institute (NKI) and Cambridge University (CAM) TMAs and 
Heidelberg tissues (Heidelberg). The graph represents the percentage of PDLIM2 positive 
and negative tumors within each of these three cohorts plus the NIB cohort from Fig. 1. The 
number of tumors in each cohort is shown in brackets. B: Representative micrograph images 
illustrating PDLIM2-negative and -positive tumor staining within each cohort showing 
negative (0), low (1) or moderate-high (2 or 3) staining intensities. Scale bars are 50µm (NIB, 
Heidelberg) or 25µm (NKI, CAM). C: Graph shows total PDLIM2-negative and -positive 
TNBCs across all four cohorts. p-value determined using the Student’s t-test. D: The 
Heatmap depicts TNBC tumor subtypes from the RATHER NKI and CAM cohorts, 
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determined from an 80-gene signature according to Burstein et al, [6], as described in 
supplementary methods. E: Graph showing the percentage of PDLIM2-positive and -negative 
tumors within each TNBC subtype in the RATHER cohorts, determined from 80-gene 
signature as in D, NKI n=70, CAM n=45. In D, E: TNBC subtypes described by Burstein et 
al, [6] are denoted as: MES: Mesenchymal, BLIA: Basal-like Immune-Activated, BLIS: 
Basal-like ImmunoSuppressed, LAR: Luminal Androgen Receptor. 
 
Figure 3:  
PDLIM2 retention at the cytoplasm in TNBC and correlation with adhesion signaling. 
A: Representative micrographs of a PDLIM2-positive tumor from each cohort examined, 
with higher magnification shown in lower panels to highlight PDLIM2 localization at the 
cytoplasm/membrane and lack of nuclear staining. B: PDLIM2 subcellular localization 
within the TNBC cells was scored for each PDLIM2-positive tumor, and scores are presented 
in graphs as percentage of positive PDLIM2-tumors for each cohort. (The RATHER-CAM 
samples were omitted from these analyses as diffuse staining in some samples confounded a 
distinct localization score). C: Overall localization of PDLIM2 is shown as the percentage of 
all PDLIM2-positive TNBCs across the three cohorts, n=99. Statistical significance was 
analyzed using a Student’s t-test. D: Box and whiskers plots of RPPA data illustrating 
distribution and median of expression values of proteins differentially expressed in PDLIM2-
negative (NEG) versus –positive (POS) tumors from the RATHER cohorts. Norm. RFU: 
normalized RPPA Fluorescence Units. Significant differences between negative and PDLIM2 
expression intensity from immunohistochemical analysis are also shown (IHC score 1-3); 
Wilcoxon test (Rank Sum) *p value <0.05, **p <0.005. 
 
Figure 4:  
PDLIM2 expression in Triple Negative cell lines that also express adhesion receptors 
and β-catenin 
A. Whole cell lysates were prepared from a panel of TN cell lines cultured for 48 hours in 
complete medium, and PDLIM2 expression was examined by Western blotting. Actin is 
loading control. The approximate protein molecular weights in kilodaltons (kDa) are 
indicated on the left of each western blot panel. B. PDLIM2 expression in each of the cell 
lines was quantified by densitometry and data are presented as fold difference in expression 
compared with MCF10A cells, set at 1. Mean expression ± SEM from five separate 
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experiments are shown. C, D. PDLIM2 mRNA expression was measured for PDLIM2 variant 
2 (C) and variant 3 (D) by qPCR. Primer details are listed in supplementary methods Table 2. 
Graphs represent mean ± SEM from at least 3 separate experiments. Statistical significance 
was analyzed using a Student’s t-test, comparing mRNA expression in each cell line to 
MCF10A (*P=0.045 in C). E-G: TN breast cell lines were grown under normal conditions, 
lysed and examined for expression of adhesion signaling proteins β1-integrin, E-cadherin and 
β-catenin and phospho-ser675 β-catenin by western blotting. Data are representative of at 
least 3 experiments, protein expression was quantified by densitometry as described in 
methods (G), quantification of phospho-ser675 β-catenin is included in suppl Fig. 5D. 
 
Figure 5:  
Cytoplasmic and nuclear shuttling of PDLIM2 in response to adhesion and growth 
factor signals 
A. Representative immunofluorescence micrographs from at least 3 separate experiments, 
showing PDLIM2 expression and localization in TN cell lines. The remainder of the cell 
panel is shown in Suppl. Figure 5A. Cells were co-stained with TRITC-Phalloidin (actin) and 
Hoechst (Nuclei). Scalebar is 20μm. B: Subcellular fractions were prepared from TN breast 
cells cultured for 48 hours in complete medium, and analyzed by western blotting for 
PDLIM2 expression. Fraction markers are Tubulin (Cytoplasm) and PARP (Nuclei); 
representative of at least three separate experiments. C: MCF10A were plated on polyhema-
treated petri dishes to prevent adhesion for 24hr (suspension), followed by re-plating on 
tissue-culture treated plates to allow reattachment for 24 hr. PDLIM2 expression and 
localization was compared with adherent cells by subcellular fractionation and western 
blotting. A representative experiment of three is shown. D: Graph shows densitometric 
quantification of PDLIM2 expression in the cytoplasm or nuclei of adherent and suspension 
cells from 3 separate experiments. Graphs represent mean ± SEM, statistical significance was 
analyzed using Student’s t-test. E, F: MCF10A cells were serum starved followed by 
stimulation with either 10ng/ml TGF beta (TGF-β1; E) or IGF-1 (F) for up to 24 hr. Cells 
were harvested at each time-point indicated, and processed for subcellular fractionation of 
cytoplasmic and nuclear fractions which were probed for PDLIM2, signaling pathway 
markers Phospho-Smad2 (TGF-β1) or Phospho-Akt serine 473 (IGF-1), and fraction markers 
vinculin (Cytoplasm) and PARP (Nuclear) by western blotting. Arrows indicate 
phosphorylated PDLIM2. G: Quantification of PDLIM2 expression and localization 
following serum starvation in presence or absence of Growth factor stimulation for 24 hr 
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(TGF-β1; left graph, IGF-1; right graph) from at least three separate experiments. Expression 
levels were measured by densitometry, graphs represent mean ± SEM and statistical 
significance was analyzed using Student’s t-test. H: PDLIM2 expression and localization 
(grey/green) in MCF10A cells following serum starvation alone, or in presence of 10ng/ml 
TGF-β1. Representative images taken at 100X magnification of each condition from at least 
three separate experiments are shown. Co-staining with TRITC-Phalloidin (actin, red) and 
Hoechst (Nuclei, blue). Scale bars represent 20μm.*P≤0.05, **P≤0.005 in D, G. 
 
Figure 6:  
PDLIM2 expression is sufficient to activate β-catenin in TNBC 
A: Immunoblots of whole cell lysates from TN breast cell lines grown under normal 
conditions for 48 hr, were probed with active β-catenin (non-phosphorylated serine 45), total 
β-catenin, PDLIM2 and tubulin antibodies. Graph shows quantification of active β-catenin 
expression, measured by densitometry, mean expression relative to that of MCF10A cells ± 
SEM is shown. Student’s t-test analyses of significant differences in expression compared to 
those of MCF10A cells, which are set at 1; *P≤0.05, **p≤0.005, ***p≤0.0001. B: 
Immunofluorescence micrographs of TN breast cell lines grown on coverslips in complete 
medium for 24 hr. Cells were fixed and stained for antibodies against active β-catenin 
(phospho-Ser675; green) and PDLIM2 (red). Nuclei were stained with Hoechst (blue). Scale 
bars represent 20µm.  C, D:  BT549 cells (C) or HEK293T cells (D) were stably transfected 
with HA-Empty Vector (EV) or HA-PDLIM2 as described in Supplementary Methods. Cells 
were cultured under normal conditions for 48 hr and assessed for protein expression as in A. 
Graphs show quantification of active β-catenin expression (non-phospho-Ser 45), measured 
by densitometry, mean expression ± SEM, relative to that of HA-EV control cells. Data is 
from 3 separate stable clones of HA-EV and HA-PDLIM2- expressing cells. **p≤0.001, 
Student’s t-test. E: HEK293T cells stably transfected with HA-Empty Vector (EV) or HA-
PDLIM2 were assessed for β-catenin transcriptional activity using a β-catenin/TCF TOPflash 
luciferase assay as described in methods. Data from three separate experiments are presented 
as fold change ± SEM of transcriptional activity of HA-PDLIM2-expressing cells compared 
with HA-EV controls, ***p≤0.0001, Student’s t-test. F, G: Subcellular fractions of adherent 
or suspension cells were prepared for PDLIM2-positive or negative TN cell lines (F) or 
BT549 stably expressing HA-EV or HA-PDLIM2 (G). Western blots of cytoplasmic and 
nuclear fractions were probed for active β-catenin (non-phospho-Ser 45; F, or phospho-Ser 
 24 
675; G), β-catenin, PDLIM2, and fraction markers tubulin (Cytoplasm) and PARP (Nuclear), 
e: empty lane. Counterparts with additional cell lines for parts F and G are shown in Suppl. 
Figs. 6G, H.  
 
Figure 7:  
PDLIM2 suppression inhibits 3D and colony formation in vitro and growth of TNBC 
cells in vivo. 
A: Western blot analyses of suppression of PDLIM2 expression in MDA-MB-231-LUC2 
cells stably expressing shScramble (shScr) or shPDLIM2 (Clones 1, 2), used for in vivo 
studies. PDLIM2 expression was quantified by densitometry, normalized to shScr1 levels, 
n=5. ***p<0.0005, Student’s t-test. B: Colony formation by MDA-MB-231-LUC2 clones 
was assessed by plating efficiency assay, n=3. C: Scatter Plot showing decreased tumor 
burden of tumor cells with PDLIM2 suppressed. Data are whole body bioluminescence 
counts 45-49 days post-tail vein injection, with two clones each of MDA-MB-231-LUC2 
cells stably expressing shScr or shPDLIM2 (Clones 1, 2). Examples of IVIS images are also 
shown. The color scale depicts the photon flux (photons per second) emitted from animals. 
***p<0.0005, **P<0.005; One way ANOVA, Bonferroni’s post-test in B and C. D: 
Micrographs of 3D cultures formed by BT549 clones stably expressing HA-EV or HA-
PDLIM2, taken on Day 2 and 4 following plating in a 3D ‘on top’ assay as described in 
materials and methods. Original magnification is 10x. E: 3D cultures extracted from Matrigel 
were lysed and analyzed by western blotting for expression of phospho-ser675 and total β-
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PROTEIN Neg vs Pos IHC Score 1 IHC Score 2 IHC Score 3
mTor 0.003 0.065 0.012 0.015
Phospho-Beta Catenin Ser675 0.007 0.254 0.024 0.006
Ki67 0.015 0.064 0.009 0.549
Phospho-Met Tyr1349 0.031 0.480 0.030 0.098
Fibronecn 0.040 0.141 0.018 0.806
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